Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kyozo Tsukamoto is active.

Publication


Featured researches published by Kyozo Tsukamoto.


Journal of Immunological Methods | 1986

AN IMPROVED COLORIMETRIC ASSAY FOR INTERLEUKIN 2

Hiroko Tada; Osamu Shiho; Ken ichi Kuroshima; Masaru Koyama; Kyozo Tsukamoto

Mosmanns method for measuring the number of viable cells with a tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium bromide (MTT), was modified to make it possible to measure a large number of interleukin 2 (IL-2) samples at one time with less labor and more accuracy. Each step of the method was examined in detail and modified (the modified MTT method). An IL-2-dependent mouse natural killer cell line, NKC3, was used as an indicator cell line. The incubation period before adding MTT was reduced to 24 h, A solution of 10% sodium dodecyl sulfate-0.01 N HCl was used to dissolve the MTT formazan produced. We have compared the values obtained by the modified MTT method and the conventional [3H]thymidine method (3H-TdR method), and confirmed that the estimates of IL-2 content were almost equal. The variation of IL-2 content measured by both methods was within 5% in terms of the standard error.


Applied Microbiology and Biotechnology | 1986

Production of human monoclonal antibodies by heterohybridomas

Kazuaki Kitano; Yasushi Shintani; Yuzo Ichimori; Kyozo Tsukamoto; Seijiro Sasai; Makoto Kida

SummaryMouse human-human heterohybridomas secreting human monoclonal antibodies (MoAb) against tetanus toxoid and hepatitis B virus surface antigen were effectively cultivated in a medium containing a serum substitute called GFS, a 55% to 70% ammonium sulphate fraction of serum from adult cattle. A perfusion culture system using a jar fermentor equipped with a cell sedimentation column with a double jacket was developed and applied to produce human MoAb. In this fermentor, maximum cell density of a heterohybridoma reached 1.2×107 cells/ml and MoAb was continuously accumulated at a constant rate for at least 40 days; this led to the production of more than one gram of human MoAb using a culture vessel with a 1-1 working volume.


Biochemical and Biophysical Research Communications | 1985

Comparison of the biological properties of purified natural and recombinant human interleukin-2

Ken ichi Naruo; Shuji Hinuma; Koichi Kato; Masaru Koyama; Hiroko Tada; Osamu Shiho; Kyozo Tsukamoto

We compared the biological properties of the purified recombinant human IL-2 derived from E. coli with those of purified natural IL-2. Both had almost the same specific in vitro activities on a weight basis to support long-term proliferation of IL-2 dependent human peripheral blood lymphocytes, a mouse killer T cell line, and a mouse natural killer cell line; induce killer cells in normal mouse spleen cells; and induce antibody forming cells in nude mouse spleen cells. No differences in these biological activities were found between two forms of natural IL-2 that were separable by reverse phase high performance liquid chromatography.


Biochemical and Biophysical Research Communications | 1985

Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen

Yuzo Ichimori; Kazunori Sasano; Hiroko Itoh; Shinya Hitotsumachi; Yoshiaki Kimura; Kenji Kaneko; Makoto Kida; Kyozo Tsukamoto

Mouse-human heterohybrids (M X H) were constructed and compared with other cell lines (human or mouse) as parental cells to obtain hybrids secreting human monoclonal antibody (MoAb). One of the M X H lines, HM-5, was far superior to the others and useful for establishing hybrids secreting human MoAb. Using HM-5 as a parental cell line, we have obtained 2 hybrids secreting human anti-tetanus toxoid MoAb with neutralizing activity and a hybrid secreting human anti-hepatitis B virus surface antigen (HBsAg) MoAb which recognizes the a-determinant of HBsAg.


Biochemical and Biophysical Research Communications | 1982

Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes

Shuji Hinuma; Haruo Onda; Ken-Ichi Naruo; Yuzo Ichimori; Masaru Koyama; Kyozo Tsukamoto

Abstract Interleukin 2 was induced in cultures of human peripheral blood leukocytes by combined treatment with 12-O-tetradecanoylphorbol-13-acetate and a T-cell mitogen, Concanavalin A. Poly(A)-containing mRNA was isolated from these cultures and fractionated by sucrose density gradient centrifugation. When injected into Xenopus laevis oocytes, the mRNA preparation gave rise to interleukin 2 activity in the culture supernatant of the oocytes. The sucrose density gradient centrifugation analysis showed that the interleukin 2 mRNA sedimented at 10–12S, which suggests that it contains about 900–1,100 nucleotides.


Journal of Immunological Methods | 1985

Monoclonal antibodies to human interferon-γ. I. Antibodies to a synthetic carboxyl-terminal peptide

Yuzo Ichimori; Tsutomu Kurokawa; Susumu Honda; Nobuhiro Suzuki; Mitsuhiro Wakimasu; Kyozo Tsukamoto

Two types of hybridomas secreting monoclonal antibodies (MAB) against human interferon-gamma (HuIFN-gamma) were obtained by somatic cell hybridization between mouse myeloma P3U1 cells and spleen cells from BALB/c mice immunized with a conjugate of a synthetic carboxyl-terminal peptide (residues 131-146) of HuIFN-gamma and bovine thyroglobulin. One of the antibodies bound to recombinant HuIFN-gamma produced in E. coli as well as to natural HuIFN-gamma, while the others bound only to recombinant HuIFN-gamma. These 2 types of MAB did not neutralize the anti-viral activity of HuIFN-gamma. They were useful for effectively purifying recombinant HuIFN-gamma and quantitatively determining it by an enzyme-linked immunosorbent assay.


Biochemical and Biophysical Research Communications | 1987

Establishment of hybridoma secreting human monoclonal antibody against hepatitis B virus surface antigen.

Yuzo Ichimori; Kaori Harada; Shinya Hitotsumachi; Kyozo Tsukamoto

The HAT (hypoxanthine, aminopterin, thymidine) sensitive and ouabain resistant human B lymphoblastoid cell line TAW-925 was obtained from 6-thioguanine resistant B lymphoblastoid cell line WI-L2. Hybridomas were obtained at a high frequency (10(-4)-10(-5) when TAW-925 was hybridized with cells transformed with Epstein-Barr virus. Using TAW-925 as a parental cell line, we have obtained a hybridoma which stably secretes human monoclonal antibody against hepatitis B virus surface antigen.


Biochemical and Biophysical Research Communications | 1985

Purification and partial sequence analysis of human interleukin-2 derived from peripheral blood leukocytes

Koichi Kato; Ken ichi Naruo; Masaru Koyama; Kenji Kawahara; Shuji Hinuma; Hiroko Tada; Hiromu Sugino; Kyozo Tsukamoto

Human peripheral blood leukocyte-derived interleukin-2 (IL-2) was resolved by DEAE-cellulose column chromatography into three peaks of activity, IL-2A, B, and C, with isoelectric points of 7.2, 6.6, and 7.9, respectively. IL-2 A, B, and C were further purified by reverse phase high performance liquid chromatography and resolved into two apparently homogeneous peaks each with identical molecular weight: A-1 and A-2 (Mr17000); B-1 and B-2 (Mr17500); and C-1 and C-2 (Mr14400). The amino acid compositions and partial NH2-terminal amino acid sequences of these molecular species were consistent with those predicted from IL-2 cDNA sequences derived from Jurkat and peripheral blood leukocytes.


Biochemical and Biophysical Research Communications | 1985

Production of cytotoxic factor(s) in human T cell lines transformed by a human retrovirus

Shuji Hinuma; Ken-Ichi Naruo; Kyozo Tsukamoto; Kazuo Sugamura; Yorio Hinuma

Human T cell lines, MT-2, TCL-Ter, TCL-Haz, and TCL-Kan which were transformed by a human retrovirus, constitutively produced cytotoxic factor(s) (CF) in the culture supernatants. In these cell lines, MT-2 produced the largest amount of CF. The amount of CF produced by MT-2 was 9-10 or 3-4 times larger than that produced by a human B cell line, RPMI 1788, or normal peripheral blood leukocytes stimulated with mitogens and phorbol ester. The kinetics of the production by MT-2 was similar in media with and without serum. The activity was stable at 56 degrees C for 30 min but was lost at 80 degrees C for 30 min and at pH 2 for 20 hr. On gel filtration, the molecular weight of the factor produced by MT-2 was approximately 90,000. On isoelectric focusing, the activity was recovered in the fraction at pH 6.5-7.0.


Cytotechnology | 1991

Effective production of anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies by serum-free culture of hybridomas.

Kazuaki Kitano; Yuzo Ichimori; Hidekazu Sawada; Susumu Iwasa; Seijiro Sasai; Kyozo Tsukamoto

Two hybridoma systems, mouse·human-human (m·h-h) heterohybridoma and human-human (h-h) hybridoma, have been established, and hybridomas secreting anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies (MoAbs), both having a neutralizing activity have been obtained. Cell-line improvement was shown to be an efficient method for improving the productivity in a cell culture process. Two kinds of serum-free media, GFS (a serum substitute)-containing media and polyethylene glycol (PEG)-containing media, have been established to produce human MoAbs. m·h-h Heterohybridomas could be cultivated for a long period by perfusion culture in an agitation vessel, but h-h hybridomas could not. We found that h-h hybridomas show growth-associated antibody production kinetics and established two kinds of long-term cultivation systems: continuous perfusion culture and semicontinuous immobilized perfusion culture. We also scaled up batch culture and short-term perfusion culture to 200-L and 50-L fermentors, respectively. Processes for large-scale purification from the culture supernatants of both GFS- and PEG-containing serum-free media have also been developed.Two hybridoma systems, mouse.human-human (m.h-h) heterohybridoma and human-human (h-h) hybridoma, have been established, and hybridomas secreting anti-tetanus toxoid and anti-HBsAg human monoclonal antibodies (MoAbs), both having a neutralizing activity have been obtained. Cell-line improvement was shown to be an efficient method for improving the productivity in a cell culture process. Two kinds of serum-free media, GFS (a serum substitute)-containing media and polyethylene glycol (PEG)-containing media, have been established to produce human MoAbs. m.h-h Heterohybridomas could be cultivated for a long period by perfusion culture in an agitation vessel, but h-h hybridomas could not. We found that h-h hybridomas show growth-associated antibody production kinetics and established two kinds of long-term cultivation systems: continuous perfusion culture and semi-continuous immobilized perfusion culture. We also scaled up batch culture and short-term perfusion culture to 200-L and 50-L fermentors, respectively. Processes for large-scale purification from the culture supernatants of both GFS- and PEG-containing serum-free media have also been developed.

Collaboration


Dive into the Kyozo Tsukamoto's collaboration.

Top Co-Authors

Avatar

Yuzo Ichimori

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Tsutomu Kurokawa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Masakazu Kikuchi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Shuji Hinuma

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Yukio Sugino

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Masaru Koyama

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Mitsuhiro Wakimasu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Seijiro Sasai

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Hiromu Sugino

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kazuaki Kitano

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge